During the past decade, Ballarat Oncology & Haematology Services conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 5 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ballarat Oncology & Haematology Services" #1 sponsor was "Pfizer" with 4 trials, followed by "Australasian Gastro-Intestinal Trials Group" with 2 trials sponsored, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 2 trials sponsored, "Bioverativ, a Sanofi company" with 2 trials sponsored and "BeiGene" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ballarat Oncology & Haematology Services" #1 collaborator was "Academic and Community Cancer Research United" with 2 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator, "Amgen" with 1 trials as a collaborator, "Bayer" with 1 trials as a collaborator and "Canadian Cancer Trials Group" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Ballarat Oncology & Haematology Services" are "Gastro-Oesophageal Cancer" (2 trials), "Agglutinin Disease, Cold" (1 trials), "BRCA 1 Gene Mutation" (1 trials), "BRCA 2 Gene Mutation" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Ballarat Oncology & Haematology Services" in a lesser frequency.

Most popular intervention types in "Ballarat Oncology & Haematology Services" are "Drug" (13 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (3 trials), "Axitinib (AG-013736)" (2 trials), "Nivolumab" (2 trials), "Placebo" (2 trials) and "Regorafenib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Ballarat Oncology & Haematology Services" are 12 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Ballarat Oncology & Haematology Services". undefined are not yet recruiting, 2 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Ballarat Oncology & Haematology Services, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Ballarat Oncology & Haematology Services, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Ballarat Oncology & Haematology Services has several departments that took part in Clinical trials: "Ballarat Oncology and Haematology Services" - 3 trials